Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)

NCT07524114 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT07524114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07524114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
Lead sponsor
University Health Network, Toronto
Phase
Observational
Overall status
Recruiting
Start date
March 31, 2026
Completion date
March 31, 2031
Enrollment
7,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastrointestinal cancer, genitourinary cancer, gynecologic cancer, head and neck cancer, lung cancer, melanoma, pancreatobiliary cancer, rare cancer, unknown primary tumors